AHN - Experimental Drug Shrinks Prostrate Cancer Tumors, Increases Survival Chances

Vittorio Hernandez - AHN News Writer Los Angeles, CA (AHN) - Abiraterone, an experimental cancer drug under trial, has potential for shrinking prostate tumors at a fast rate and giving cancer patients double the chance of survival in 70 to 80 percent of patients with aggressive cancers. The study has a small trial sample of 21 patients, although the medication was first tested in over 250 men with similar positive results. Cancer and urology experts agree Abiraterone holds promise. "There is a general sense in the prostate cancer community that this agent is extremely promising and is very likely to have an important role n the management of prostate cancer patients," said Dr. Howard Sandler, a radiation oncologist. Dr. Robert Reiter, a urologist at UCLA's Jonsson Comprehensive Cancer Center, told the Los Angeles Times, "It's... [read full story]